MD3519398T2 - Compus de piridină - Google Patents

Compus de piridină

Info

Publication number
MD3519398T2
MD3519398T2 MDE20190863T MDE20190863T MD3519398T2 MD 3519398 T2 MD3519398 T2 MD 3519398T2 MD E20190863 T MDE20190863 T MD E20190863T MD E20190863 T MDE20190863 T MD E20190863T MD 3519398 T2 MD3519398 T2 MD 3519398T2
Authority
MD
Moldova
Prior art keywords
pharmaceutically acceptable
acceptable salts
relates
pyridine compound
compound
Prior art date
Application number
MDE20190863T
Other languages
English (en)
Inventor
Hiroaki Inagaki
Yoshihiro Shibata
Hidenori Namiki
Hideaki Kageji
Kiyoshi Nakayama
Yasuyuki Kaneta
Original Assignee
Daiichi Sankyo Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daiichi Sankyo Co Ltd filed Critical Daiichi Sankyo Co Ltd
Publication of MD3519398T2 publication Critical patent/MD3519398T2/ro

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)

Abstract

Prezenta invenţie se referă la un compus care are activitate inhibitorie selectivă a RET kinază şi sărurile acceptate farmaceutic. Această invenţie se referă, de asemenea, la metode de fabricare a unor astfel de compuşi şi a compoziţiilor farmaceutice care conţin astfel de compuşi utile în tratamentul bolilor cum ar fi cancerul.În special un compus reprezentat de formula generală (I), definită aici:sau sărurile acceptate farmaceutic
MDE20190863T 2016-09-29 2017-09-28 Compus de piridină MD3519398T2 (ro)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2016191725A JP2018052878A (ja) 2016-09-29 2016-09-29 ピリジン化合物
PCT/GB2017/052913 WO2018060714A1 (en) 2016-09-29 2017-09-28 Pyridine compound

Publications (1)

Publication Number Publication Date
MD3519398T2 true MD3519398T2 (ro) 2021-05-31

Family

ID=60020249

Family Applications (1)

Application Number Title Priority Date Filing Date
MDE20190863T MD3519398T2 (ro) 2016-09-29 2017-09-28 Compus de piridină

Country Status (32)

Country Link
US (2) US10851092B2 (ro)
EP (2) EP3519398B1 (ro)
JP (2) JP2018052878A (ro)
KR (1) KR102520543B1 (ro)
CN (2) CN113788824A (ro)
AU (2) AU2017335242C1 (ro)
BR (1) BR112019006047A2 (ro)
CA (1) CA3035860A1 (ro)
CL (1) CL2019000844A1 (ro)
CO (1) CO2019004034A2 (ro)
CY (1) CY1123988T1 (ro)
DK (1) DK3519398T3 (ro)
EA (1) EA037103B1 (ro)
EC (1) ECSP19030134A (ro)
ES (1) ES2868748T3 (ro)
HR (1) HRP20210447T1 (ro)
HU (1) HUE054824T2 (ro)
IL (1) IL265630B (ro)
LT (1) LT3519398T (ro)
MA (2) MA46337B1 (ro)
MD (1) MD3519398T2 (ro)
MX (1) MX2019003747A (ro)
PE (1) PE20190805A1 (ro)
PH (1) PH12019500480A1 (ro)
PL (1) PL3519398T3 (ro)
PT (1) PT3519398T (ro)
RS (1) RS61640B1 (ro)
SG (1) SG11201901937WA (ro)
SI (1) SI3519398T1 (ro)
UA (1) UA123964C2 (ro)
WO (1) WO2018060714A1 (ro)
ZA (1) ZA201902232B (ro)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY194262A (en) 2015-11-02 2022-11-25 Blueprint Medicines Corp Inhibitors of ret
JP2018052878A (ja) * 2016-09-29 2018-04-05 第一三共株式会社 ピリジン化合物
WO2019143994A1 (en) 2018-01-18 2019-07-25 Array Biopharma Inc. Substituted pyrazolyl[4,3-c]pyridinecompounds as ret kinase inhibitors
CN111971286B (zh) 2018-01-18 2023-04-14 阿雷生物药品公司 作为RET激酶抑制剂的取代的吡咯并[2,3-d]嘧啶化合物
JP7422084B2 (ja) 2018-04-03 2024-01-25 ブループリント メディシンズ コーポレイション Ｒｅｔ変化を有する癌の処置において使用するためのｒｅｔ阻害剤
CA3129665A1 (en) 2019-03-21 2020-09-24 Onxeo A dbait molecule in combination with kinase inhibitor for the treatment of cancer
CN114761006A (zh) 2019-11-08 2022-07-15 Inserm(法国国家健康医学研究院) 对激酶抑制剂产生耐药性的癌症的治疗方法
CN115087463A (zh) * 2019-11-18 2022-09-20 中外制药株式会社 并用药物
CN113121524B (zh) 2019-12-31 2023-04-25 南京创济生物医药有限公司 杂环亚砜亚胺化合物及其中间体、制备方法和应用
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
WO2021164742A1 (zh) * 2020-02-20 2021-08-26 广州白云山医药集团股份有限公司白云山制药总厂 喹啉类化合物
WO2021164741A1 (zh) * 2020-02-20 2021-08-26 南京明德新药研发有限公司 苯基双酰胺类化合物
WO2022238706A1 (en) 2021-05-14 2022-11-17 Bp Asset Viii, Inc. Ret inhibitor for the treatment of ret altered medullary thyroid cancer or ret altered non-small cell lung cancer
AU2022463015A1 (en) 2021-10-22 2024-05-09 Tract Pharmaceuticals, Inc. Methods and compositions for treating chronic inflammatory injury, metaplasia, dysplasia and cancers of epithelial tissues
CN115090331B (zh) * 2022-07-21 2023-05-16 扬州大学 超分子手性催化剂、其制备方法及其催化d-a反应的应用

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI284639B (en) 2000-01-24 2007-08-01 Shionogi & Co A compound having thrombopoietin receptor agonistic effect
AU2004270733B2 (en) 2003-09-11 2011-05-19 Itherx Pharma, Inc. Cytokine inhibitors
US20090076075A1 (en) 2006-03-02 2009-03-19 Frederic Henri Jung Quinoline derivatives
JP2009528335A (ja) 2006-03-02 2009-08-06 アストラゼネカ アクチボラグ キナゾリン誘導体
WO2007113565A1 (en) 2006-04-06 2007-10-11 Astrazeneca Ab Naphthyridine derivatives as anti-cancer agents
WO2007113548A1 (en) 2006-04-06 2007-10-11 Astrazeneca Ab Naphthyridine derivatives
FR2933700B1 (fr) 2008-07-08 2010-07-30 Sanofi Aventis Derives de pyridino-pyridinones, leur preparation et leur application en therapeutique
BRPI1008308B8 (pt) * 2009-02-27 2021-05-25 Teijin Pharma Ltd processo para produzir um composto
MX2012001974A (es) 2009-08-19 2012-04-11 Ambit Biosciences Corp Compuestos de biarilo y metodos de uso de los mismos.
DK2470173T3 (en) 2009-08-25 2016-06-06 Abraxis Bioscience Llc Combination therapy of nanoparticle composition of the taxane and the hedgehog inhibitors
CN102946881A (zh) 2010-04-23 2013-02-27 奇尼塔公司 抗病毒化合物
EP2651930B1 (en) 2010-12-16 2015-10-28 Boehringer Ingelheim International GmbH Biarylamide inhibitors of leukotriene production
US9212209B2 (en) 2012-07-13 2015-12-15 Indiana University Research And Technology Corporation Screening methods for spinal muscular atrophy
PT2970191T (pt) 2013-03-15 2017-03-23 Glaxosmithkline Ip Dev Ltd Derivados de piridina como inibidores da quinase rearranjada durante transfecção(ret)
KR20160055170A (ko) 2013-08-30 2016-05-17 암비트 바이오사이언시즈 코포레이션 바이아릴 아세트아미드 화합물 및 이의 사용 방법
GB201321146D0 (en) 2013-11-29 2014-01-15 Cancer Rec Tech Ltd Quinazoline compounds
US9783522B2 (en) * 2014-04-24 2017-10-10 Mitsubishi Tanabe Pharma Corporation 2-amino-pyridine and 2-amino-pyrimidine derivatives and medicinal use thereof
JP6538154B2 (ja) * 2014-09-10 2019-07-03 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ Ｒｅｔ（ｒｅａｒｒａｎｇｅｄ ｄｕｒｉｎｇ ｔｒａｎｓｆｅｃｔｉｏｎ）キナーゼ阻害剤としてのピリジン誘導体
JP6538153B2 (ja) * 2014-09-10 2019-07-03 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ Ｒｅａｒｒａｎｇｅｄ ｄｕｒｉｎｇ ｔｒａｎｓｆｅｃｔｉｏｎ（ｒｅｔ）阻害剤としての新規な化合物
JP6899323B2 (ja) 2014-10-14 2021-07-07 ラ ホーヤ インスティテュート オブ アレルギー アンド イミュノロジー 低分子量タンパク質チロシンホスファターゼの阻害剤、及びその使用
CN104844589B (zh) 2014-12-26 2018-04-20 中国科学院合肥物质科学研究院 一种pi3k激酶抑制剂
WO2016127074A1 (en) * 2015-02-06 2016-08-11 Blueprint Medicines Corporation 2-(pyridin-3-yl)-pyrimidine derivatives as ret inhibitors
SI3322706T1 (sl) 2015-07-16 2021-04-30 Array Biopharma, Inc. Substituirane pirazolo(1,5-A)piridinske spojine kot zaviralci ret-kinaze
JP2018052878A (ja) * 2016-09-29 2018-04-05 第一三共株式会社 ピリジン化合物

Also Published As

Publication number Publication date
EP3519398A1 (en) 2019-08-07
EA201990833A1 (ru) 2019-10-31
ZA201902232B (en) 2022-12-21
MA46337B1 (fr) 2021-04-30
IL265630B (en) 2021-10-31
US20210163464A1 (en) 2021-06-03
CY1123988T1 (el) 2022-05-27
HUE054824T2 (hu) 2021-10-28
US20200039974A1 (en) 2020-02-06
CN110036007A (zh) 2019-07-19
RS61640B1 (sr) 2021-04-29
UA123964C2 (uk) 2021-06-30
JP2018052878A (ja) 2018-04-05
MA54910A (fr) 2022-04-13
JP2019534871A (ja) 2019-12-05
HRP20210447T1 (hr) 2021-07-23
PL3519398T3 (pl) 2021-06-28
MA46337A (fr) 2019-08-07
US10851092B2 (en) 2020-12-01
CO2019004034A2 (es) 2019-07-10
EP3828178A1 (en) 2021-06-02
KR20190086442A (ko) 2019-07-22
MX2019003747A (es) 2019-09-19
ES2868748T3 (es) 2021-10-21
BR112019006047A2 (pt) 2019-06-25
LT3519398T (lt) 2021-05-10
PT3519398T (pt) 2021-03-24
AU2017335242C1 (en) 2021-12-09
AU2021261899A1 (en) 2021-12-02
ECSP19030134A (es) 2019-08-30
AU2017335242B2 (en) 2021-08-19
KR102520543B1 (ko) 2023-04-10
CA3035860A1 (en) 2018-04-05
PH12019500480A1 (en) 2019-08-05
SI3519398T1 (sl) 2021-07-30
IL265630A (en) 2019-05-30
CN110036007B (zh) 2021-10-15
EA037103B1 (ru) 2021-02-05
SG11201901937WA (en) 2019-04-29
AU2017335242A1 (en) 2019-05-02
CL2019000844A1 (es) 2019-06-07
JP7098609B2 (ja) 2022-07-11
CN113788824A (zh) 2021-12-14
WO2018060714A1 (en) 2018-04-05
PE20190805A1 (es) 2019-06-10
DK3519398T3 (da) 2021-03-29
EP3519398B1 (en) 2021-02-24

Similar Documents

Publication Publication Date Title
MD3519398T2 (ro) Compus de piridină
MX2023001876A (es) Derivados de rapamicina.
MD3394033T2 (ro) Compuși heterociclici ca imunomodulatori
EA201991693A1 (ru) Производное пиридина в качестве ингибитора ask1 и способ его получения и применения
MD3377488T2 (ro) Compuși heterociclici ca imunomodulatori
MD3269370T2 (ro) Compus pirimidinic condensat nou sau sare a acestuia
CL2020000886A1 (es) Derivados de 1-benzil-2-imino-4-fenil-5-oxoimidazolidina como inhibidores de la proteasa del vih.
EA201891063A1 (ru) Производные дигидроимидазопиразинона, применимые в лечении рака
EA201690752A1 (ru) Ингибиторы g12c kras
EA201991884A2 (ru) Ингибиторы g12c kras
SG10201811384TA (en) Mnk inhibitors and methods related thereto
EA201691803A1 (ru) Ингибиторы калликреина плазмы человека
EA201891703A1 (ru) Соединения бензопиразола и их аналоги
PH12018500061A1 (en) Oxysterols and methods of use thereof
MX2019003143A (es) Compuesto heterociclico sustituido con alquinilo, su metodo de preparacion y su uso medico.
TN2015000391A1 (en) Compounds and compositions for the treatment of parasitic diseases
EA201692000A1 (ru) Макроциклические производные пиридина
EA201692003A1 (ru) Макроциклические производные пиримидина
AU2015211852A1 (en) Heterocyclic sulfonamide derivative and medicine comprising same
EA201792425A1 (ru) Трициклические соединения и их применение в качестве ингибиторов фосфодиэстераз
SA520411635B1 (ar) A2a مشتق حلقي مدمج كمثبط مستقبل
MX2017000208A (es) Derivados de quinolizinona como inhibidores de pi3k.
MX2018009458A (es) Derivado de sulfonamida heterociclico y medicina que contiene el mismo.
EA201692300A1 (ru) Производные карбоксамида
EA201890534A1 (ru) Новые аннелированные феноксиацетамиды